Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab plus axitinib in previously treated NSCLC or cisplatin-ineligible treatment-naive urothelial cancer
2017-004345-24Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jul 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of avelumab and axitinib in non-small cell lung cancer (NSCLC) and transitional cell carcinoma (TCC) (2 cohorts), sponsored by Pfizer. Primary endpoint: Confirmed objective response. Started Jul 2018; status: completed.
02
Drugs
avelumabaxitinib
03
Conditions
non-small cell lung cancer (NSCLC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2017-004345-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004345-24.